30 July 2023

AUSTRALIA – Juno LP completes Exit of Juno Australia

Juno Pharmaceutical Limited Partners (“Juno LP”) has exited its equity investment in Juno Pharmaceuticals Australia (“Juno Australia”) to DBG Health.

Juno Australia is market leader in the development and licensing of generic and specialty medicines, with a focus on injectables used in hospitals in Australia and New Zealand. The Company operates an integrated platform that helps with supply chain and wholesale stock management, as well as the sales and marketing of products. It operates as a one-stop shop for hospital customers.

Juno Australia was founded in 2013 and is the pioneer investment of Juno LP.

MinterEllison served as legal advisers on the transaction. Read More